Margret Patecki

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Urokinase Receptor Mediates Osteoclastogenesis via M-CSF Release From Osteoblasts and the c-Fms/PI3K/Akt/NF-κB Pathway in Osteoclasts

Parnian Kalbasi Anaraki, Margret Patecki, Sergey Tkachuk et al. · Journal of Bone and Mineral Research · 2014 · 44 citations · Full text

Medicine, Cell Biology, Bone Metabolism +12

Urokinase Receptor Mediates Osteogenic Differentiation of Mesenchymal Stem Cells and Vascular Calcification via the Complement C5a Receptor

Parnian Kalbasi Anaraki, Margret Patecki, Jan Larmann et al. · Stem Cells and Development · 2013 · 44 citations

Life Sciences, Cell Biology, Molecular Biology +16